<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROGESTERONE- progesterone injection </strong><br>West-ward Pharmaceutical Corp<br></p></div>
<h1>
<span class="Bold">PROGESTERONE INJECTION, USP <br>IN SESAME OIL <br>FOR INTRAMUSCULAR USE ONLY<br>Rx only<br></span><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_fe3753b4-e04a-4077-8e87-df726703c898"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Progesterone injection, USP a progestin, is a sterile solution of progesterone in a suitable vegetable oil available for intramuscular use.</p>
<p>Progesterone occurs as a white or creamy white, crystalline powder. It is odorless and is stable in air. Practically insoluble in water, it is soluble in alcohol, acetone, and dioxane and sparingly soluble in vegetable oils.</p>
<p>It has the following structural formula:</p>
<div class="Figure"><img alt="Progesterone structural formula." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cfc12e-75d1-4284-bcc3-beadcbd27171&amp;name=progesterone-injection-1.jpg"></div>
<p>C<span class="Sub">21</span>H<span class="Sub">30</span>O<span class="Sub">2</span>           M.W. 314.47</p>
<p>Pregn-4-ene-3, 20-dione</p>
<p>Each mL contains: Progesterone 50 mg, Benzyl Alcohol 10% as preservative in Sesame Oil q.s.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_624fdf87-b1cf-43de-856b-7f365a20fa24"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Transforms proliferative endometrium into secretory endometrium.</p>
<p>Inhibits (at the usual dose range) the secretion of pituitary gonadotropins, which in turn prevents follicular maturation and ovulation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f95bcfd5-40d6-414d-a246-9c7a9bf0ff4a"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">Pharmacokinetics and Metabolism:</span></h2>
<p class="First"><span class="Italics">Absorption: </span>After intramuscular administration of 10 mg of progesterone in oil maximum plasma concentrations (geometric mean of 7 ng/mL) were reached within approximately 8 hours after injection and plasma concentrations remained above baseline for about 24 hours after injection. Injection of 10, 25, and 50 mg resulted in geometric mean values for maximum plasma concentration (C<span class="Sub">MAX</span>) of 7, 28, and 50 ng/mL, respectively.</p>
<p><span class="Italics">Distribution: </span>Progesterone is extensively bound to plasma proteins, primarily albumin (50-54%) and cortisol-binding protein (43-48%).</p>
<p><span class="Italics">Metabolism: </span>Progesterone is metabolized primarily in the liver by reduction to pregnanediol, pregnanetriol and pregnanolone. Subsequent conjugation results in the formation of glucuronide and sulfate metabolites. The mean plasma metabolic clearance rate in cycling women is 2510 ± 135 (SEM) L/day.</p>
<p><span class="Italics">Excretion: </span>The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces.</p>
<p>The pharmacokinetic data was determined in a small number of patients, limiting the precision in which population values may be estimated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6817e65b-e7ae-41a6-82b9-ae401851b511"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">Special Populations:</span></h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>: </span>The safety and effectiveness in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have not been established. Since progesterone metabolites are excreted mainly by the kidneys, progesterone should be administered with caution and careful monitoring in this patient population (see <a href="#LINK_d016329e-a093-43e5-a241-8c7c3fd82246">PRECAUTIONS</a>).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>: </span>The safety and effectiveness in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have not been established. Since progesterone is metabolized by the liver, use in patients with liver dysfunction or disease is contraindicated (see <a href="#LINK_9c0c5b57-7a94-4b2e-a8ac-7851874d8e95">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e3820285-bb16-4f19-9d5e-a40bab5e52d5"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">Drug Interactions:</span></h2>
<p class="First">The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC<span class="Sub">50</span> &lt; 01 mcM). Ketoconazole is a known inhibitor of cytochrome P450 3A4 and these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. The clinical relevance of the <span class="Italics">in vitro </span>findings is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_ebb6cf8b-78eb-410e-bfda-9f3161730b51"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">This drug is indicated in <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> and abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> due to hormonal imbalance in the absence of organic pathology, such as submucous <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">fibroids</span> or uterine cancer.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_9c0c5b57-7a94-4b2e-a8ac-7851874d8e95"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<ol class="Arabic">
<li><p class="First">Current or past history of <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, thromboembolic disorders, or cerebral <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">apoplexy</span>.</p></li>
<li><p class="First">Liver dysfunction or disease.</p></li>
<li><p class="First">Known or suspected malignancy of breast or genital organs.</p></li>
<li><p class="First">Undiagnosed <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p></li>
<li><p class="First">Missed abortion.</p></li>
<li><p class="First">Known sensitivity to progesterone injection.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_47b3821a-0d4d-4624-a9d1-6c46dd62386e"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">The physician should be alert to the earliest manifestations of thrombotic disorders (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorders</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>). Should any of these occur or be suspected, the drug should be discontinued immediately.</p>
<p>Medication should be discontinued pending examination if there is a sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or if there is a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, medication should be withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_d016329e-a093-43e5-a241-8c7c3fd82246"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_92019405-55c2-4e79-9689-1c875a92bd61"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">The pretreatment physical examination should include special reference to breast and pelvic organs, as well as a Papanicolaou smear.</p>
<p>Because progestational drugs may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, conditions which might be influenced by this condition, such as <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, cardiac, or renal dysfunction, require careful observation.</p>
<p>In cases of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in all cases of irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">per vaginum, </span>nonfunctional causes should be borne in mind, and adequate diagnostic measures undertaken.</p>
<p>Patients who have a history of psychic <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</p>
<p>The age of the patient constitutes no absolute limiting factor although treatment with progestin may mask the onset of the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">climacteric</span>.</p>
<p>The pathologist should be advised of progestin therapy when relevant specimens are submitted.</p>
<p>There are possible risks which may be associated with the use of progestin treatment, including adverse effects on carbohydrate and lipid metabolism. The dosage used may be important in minimizing these adverse effects.</p>
<p>A decrease in glucose tolerance has been observed in a small percentage of patients on estrogen-progestin combination treatment. The mechanism of this decrease is obscure.</p>
<p>For this reason, diabetic patients should be carefully observed while receiving such therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_97b0ce4d-1593-4bb6-8a61-d468b88d9f29"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Long-term intramuscular administration of Medroxyprogesterone acetate (MPA) has been shown to produce mammary tumors in beagle dogs. There is no evidence of a carcinogenic effect associated with the oral administration of MPA to rats and mice.</p>
<p>Medroxyprogesterone acetate was not mutagenic in a battery of <span class="Italics">in vitro </span>or <span class="Italics">in vivo </span>genetic toxicity assays.</p>
<p>Progesterone at high doses is an antifertility drug and high doses would be expected to impair fertility until the cessation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cbaeb729-d54f-41ea-9f7f-0663a3333228"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">The safety and effectiveness in geriatric patients (over age 65) have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b29c5e6a-5b80-47d6-a442-4c67882787d0"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e8cd887e-5d90-4e04-a20c-31ed0beddccd"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Detectable amounts of drug have been identified in the milk of mothers receiving progestational drugs. The effect of this on the nursing infant has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_b423fbc8-659e-4917-ac33-da064bb0d1fa"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; change in menstrual flow; <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; change in weight (increase or decrease); changes in cervical erosion and cervical secretions; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span> and <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, and/or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the injection area; skin sensitivity reactions consisting of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (allergic) with and without <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>A statistically significant association has been demonstrated between use of estrogen-progestin combination drugs and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. For this reason patients on progestin therapy should be carefully observed. </p>
<p>There is also evidence suggestive of an association with neuro-ocular lesions, e.g., retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>.</p>
<p>The following adverse reactions have been observed in patients receiving estrogen-progestin combination drugs: <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> in susceptible individual, <span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">premenstrual syndrome</span>, changes in libido, changes in appetite, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>-like syndrome, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, loss of scalp hair, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>The following laboratory results may be altered by the use of estrogen-progestin combination drugs: increased sulfobromophthalein retention and other hepatic function tests; coagulation tests: increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> factors VII, VIII, IX, and X; metyrapone test; pregnanediol determinations; thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in T<span class="Sup">3</span> uptake values.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e4d6a660-790a-4a2c-898a-b398ac68fef6"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Progesterone injection is administered by intramuscular injection. It differs from other commonly used steroids in that it is irritating at the place of injection.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>: </span>Five to 10 mg are given for six to eight consecutive days. If there has been sufficient ovarian activity to produce a proliferative endometrium, one can expect <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> forty-eight to seventy-two hours after the last injection. This may be followed by spontaneous normal cycles.</p>
<p><span class="Bold">Functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span>: </span>Five to 10 mg are given daily for six doses. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> may be expected to cease within six days. When estrogen is given as well, the administration of progesterone is begun after two weeks of estrogen therapy. If menstrual flow begins during the course of injections of progesterone, they are discontinued.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_08f10393-57a7-442d-aa2e-8aeb3cc280b0"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Progesterone Injection USP, 50 mg/mL is available in 10 mL multiple dose vials, individually boxed.</p>
<p>(NDC 0143-9725-01)</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Rev. 05/2011</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_88898212-55b0-4648-b45f-fbe2e4990b69"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">PATIENT INFORMATION</span></h1>
<p class="First"><span class="Bold">FOR THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">AMENORRHEA</span> (ABSENCE OF MENSES IN WOMEN WHO HAVE PREVIOUSLY HAD A MENSTRUAL PERIOD) OR ABNORMAL <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">UTERINE BLEEDING</span> DUE TO HORMONAL IMBALANCE.</span></p>
<p>Please read this information carefully before you start to use progesterone injection and each time your prescription is renewed, in case anything has changed. This leaflet does not take the place of discussions with your doctor. If you still have any questions, ask your doctor or healthcare provider.</p>
<p><span class="Bold">About progesterone injection<br></span>Progesterone injection is a sterile injectable solution containing the natural female hormone called progesterone. Progesterone injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> and abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> due to progesterone deficiency.</p>
<p><span class="Bold">Understanding the role of progesterone injection in the treatment of your menstrual irregularities.<br></span>Progesterone is one of the hormones essential for regular menstrual periods. If your doctor has determined your body does not produce enough progesterone on its own, progesterone injection may be prescribed to provide the progesterone you need.</p>
<p>When you do not produce enough progesterone, menstrual irregularities can occur. </p>
<p>Progesterone injection can provide you with the progesterone needed during a normal menstrual cycle.</p>
<p><span class="Bold">Possible side effects of progesterone injection<br></span>The following side effects have been reported with progesterone injection. Consult your doctor if you experience any of the side effects mentioned below, or other side effects.</p>
<ul class="Disk">
<li><p class="First">breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p></li>
<li><p class="First">spotting</p></li>
<li><p class="First">changes in menstrual flow</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span></p></li>
<li><p class="First">change in weight (increase or decrease)</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, irritation, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and/or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the injection area</p></li>
<li><p class="First">general <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span></p></li>
<li><p class="First">yellow discoloration of skin or white of eyes</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, discharge from the nipple</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> or growth of new hair</p></li>
<li><p class="First">mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>*</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p></li>
<li><p class="First">anaphylactoid (life-threatening allergic) reaction with symptoms that may include a sense of uneasiness or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; fast, throbbing heartbeat; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; difficult breathing; <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the throat; <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p></li>
</ul>
<p>*If you experience <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, do not drive or operate machinery.</p>
<p><span class="Bold">When you should not use progesterone injection</span></p>
<ul class="Disk">
<li><p class="First">If you are allergic to progesterone, progesterone-like drugs, benzyl alcohol or sesame oil/seeds.</p></li>
<li><p class="First">If you have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> which has not been evaluated by your doctor.</p></li>
<li><p class="First">If you have liver disease.</p></li>
<li><p class="First">If you have known or suspected cancer of the breast or genital organs.</p></li>
<li><p class="First">If you have a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> and your physician suspects some tissue is still in the uterus.</p></li>
<li><p class="First">If you have or have had blood clots in the legs, lungs, eyes, or elsewhere.</p></li>
</ul>
<p><span class="Bold">Risks of progesterone injection</span></p>
<p>Abnormal blood clotting. Blood clots have been reported with the use of estrogens and progestational drugs (alone or in combination). If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (by cutting off blood to part of the brain), a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> (by cutting off blood to part of the heart), a <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> (by cutting off blood to part of the lungs), or other problems. Any of these conditions may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious long-term <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Call your doctor immediately if you suspect you have any of these conditions. He or she may advise you to stop using this drug.</p>
<p><span class="Bold">Precautions<br></span>Be alert for unusual signs and symptoms. If any of these warning signals (or any other unusual symptoms) happen while you are using progesterone injection, call your doctor immediately:</p>
<ul class="Disk">
<li><p class="First">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in the calves or chest, a sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">coughing blood</span> indicating possible clots in the legs, heart, or lungs.</p></li>
<li><p class="First">Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, faintness, or changes in vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of an arm or leg indicating possible clots in the brain or eye.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span>, which could be associated with fibrocystic disorders, fibroadenoma, or breast cancer. (Ask your doctor or healthcare provider to show you how to examine your breasts monthly.)</p></li>
<li><p class="First">Yellowing of the skin and/or white of the eyes indicating possible liver problems.</p></li>
</ul>
<p><span class="Bold">How progesterone injection works<br></span>Progesterone injection is intended for administration by injection into a <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>. Following injection, the medication is absorbed into the bloodstream.</p>
<p><span class="Bold">Other information</span></p>
<ol class="Arabic">
<li><p class="First">Your doctor has prescribed this drug for you and you alone. Do not give this drug to anyone else.</p></li>
<li><p class="First">This medication was prescribed for your particular medical condition. Do not use it for another condition.</p></li>
<li><p class="First">Keep this and all drugs out of the reach of children.</p></li>
</ol>
<p><span class="Bold">How to use progesterone injection<br></span>Progesterone injection will be administered to you by a healthcare provider or your caregiver. Your doctor will provide instructions regarding the dose and manner in which the medication should be injected. Follow your doctor’s instructions closely. If you have any questions about product administration, ask your doctor or healthcare provider.</p>
<p><span class="Bold">How Supplied<br></span>Progesterone Injection, USP 50 mg/mL is available in 10 mL multiple dose vials. Vials are individually boxed.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Do not use progesterone injection after the expiration date which is printed on the vial label.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
<p>Manufactured by:<br>Hikma Farmaceutica (Portugal) S.A. </p>
<p>Distributed by:<br>West-ward Pharmaceutical Corp.<br>Eatontown, NJ 07724 USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_45568bcc-38aa-4313-9b5d-2403b7d619f3"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Progesterone Injection, USP<br>500 mg/10 mL (50 mg/mL)<br>NDC 0143-9725-01</p>
<div class="Figure">
<img alt="Progesterone Injection, USP 500 mg/10 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cfc12e-75d1-4284-bcc3-beadcbd27171&amp;name=progesterone-injection-2.jpg"><p class="MultiMediaCaption"></p>
</div>
<div class="Figure">
<img alt="Progesterone Injection, USP 500 mg/10 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cfc12e-75d1-4284-bcc3-beadcbd27171&amp;name=progesterone-injection-3.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROGESTERONE 		
					</strong><br><span class="contentTableReg">progesterone injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9725</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROGESTERONE</strong> (PROGESTERONE) </td>
<td class="formItem">PROGESTERONE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SESAME OIL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9725-01</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091033</td>
<td class="formItem">10/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>West-ward Pharmaceutical Corp
							(001230762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hikma Farmaceutica</td>
<td class="formItem"></td>
<td class="formItem">452742943</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5e444913-7afc-42d3-abf2-6c5dd2d51d7d</div>
<div>Set id: 83cfc12e-75d1-4284-bcc3-beadcbd27171</div>
<div>Version: 2</div>
<div>Effective Time: 20101202</div>
</div>
</div> <div class="DistributorName">West-ward Pharmaceutical Corp</div></p>
</body></html>
